The p53 protein, encoded by the TP53 gene, serves as a critical tumor suppressor, playing a
vital role in maintaining genomic stability and regulating cellular responses to stress …

While traditional high-dose chemotherapy can effectively prolong the overall survival of
acute myeloid leukemia (AML) patients and contribute to better prognostic outcomes, the …

Acute myeloid leukemia (AML) kills 75% of patients and represents a major clinical
challenge with a need to improve on current treatment approaches. Targeting sphingosine …

Acute myeloid leukemia (AML) is a stem cell-driven malignancy of the blood forming
(hematopoietic) system. Despite of high dose chemotherapy with toxic side effects, many …

It is known that cell culture density can modulate the drug resistance of acute myeloid
leukemia (AML) cells. In this work, we studied the drug sensitivity of AML cells in high …

Purpose of study Despite the various therapeutic options introduced for AML treatment,
therapy resistance and relapse are still the main obstacles. It is well known that alterations in …

In October 2020, the FDA granted regular approval to venetoclax (ABT-199) in combination
with hypomethylating agents for newly-diagnosed acute myeloid leukemia (AML) in adults …

The current scientific literature has extensively explored the potential role of proteasome
inhibitors (PIs) in the NF-κB pathway of leukemia and lymphoma. The ubiquitin-proteasome …

Introduction Acute myeloid leukemia (AML) is a highly heterogeneous malignancy caused
by various genetic alterations and characterized by the accumulation of immature myeloid …

Bone marrow aging is associated with multiple cellular dysfunctions, including perturbed
haematopoiesis, the propensity to haematological transformation, and the maintenance of …